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Mexico; 4Johnson and Johnson International, New Brunswick, NJ, USAA B S T R A C TObjective: To assess the cost-effectiveness of canagliﬂozin versus
sitagliptin for the treatment of type 2 diabetes mellitus (T2DM) as
an add-on to metformin in Mexico. Methods: A validated model
(Economic and Health Outcomes [ECHO]-T2DM) was used to estimate
the cost-effectiveness of canagliﬂozin 300 or 100 mg versus sitagliptin
100 mg in patients with T2DM inadequately controlled on metformin
monotherapy. Data from a head-to-head, phase III clinical trial,
including patients’ baseline demographic characteristics, biomarker
values, and treatment effects, were used to simulate outcomes and
resource use over 20 years from the perspective of the Mexican health
care system. Costs of complications and adverse events were tailored
to the Mexican setting and discounted at 5%. Cost-effectiveness was
assessed using willingness-to-pay thresholds equivalent to 1 times
the gross domestic product per capita (locally perceived to be “very
cost-effective”) and 3 times the gross domestic product per capita
(locally perceived to be “cost-effective”) on the basis of recommenda-
tions of the Mexican government and the World Health Organization.
Results: Owing primarily to better glycated hemoglobin (HbA1c),
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ndence to: Cheryl Neslusan, Janssen Global Servic300 and 100 mg were associated with an incremental beneﬁt of 0.16
and 0.06 quality-adjusted life-years (QALYs) versus sitagliptin 100 mg,
respectively, over 20 years. The mean differences in cost for canagli-
ﬂozin 300 and 100 mg versus sitagliptin 100 mg were Mexican pesos
(MXP) 1797 (US $134) and MXP 7262 (US $540), respectively, resulting in
a cost per QALY gained of MXP 11,210 (US $834) and MXP 128,883 (US
$9590), respectively. Both of these cost-effectiveness ratios are below
the very cost-effective willingness-to-pay threshold in Mexico. The
general ﬁnding that canagliﬂozin is cost-effective versus sitagliptin in
Mexico was supported by sensitivity analyses. Conclusion: In Mexico,
both doses of canagliﬂozin are likely to be cost-effective versus
sitagliptin in patients with T2DM who have inadequate glucose
control on metformin, primarily because of better biomarker control
and higher QALYs.
Keywords: cost-effectiveness, dipeptidyl peptidase-4 inhibitor, SGLT2
inhibitor, type 2 diabetes.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The number of people with diabetes in Latin American countries
is growing, likely because of widespread increases in obesity in
the region, and it is expected to increase by approximately 60%,
from 24.1 million today to 38.5 million by 2035 [1]. About 90% of
patients have type 2 diabetes mellitus (T2DM) [2]. In Mexico, the
prevalence of diagnosed patients increased from 7.3% of the
population in 2006 to 9.2% in 2012 [3], and it is believed that
many cases remain undiagnosed [2]. Diabetes has been the
leading cause of death since 2000, and was estimated to account
for nearly 14% of deaths in 2009 [4].
T2DM imposes a signiﬁcant economic burden on health care
in Latin America due to the increasing prevalence and chronicnature of T2DM and associated comorbidities. There are direct
costs incurred in managing the hyperglycemia associated with
T2DM. It is notable, however, that most of the costs are
attributable to T2DM-related complications (e.g., myocardial
infarction, stroke, nephropathy, neuropathy, and retinopathy),
the rates of which are inversely related to disease control [5]. In
Mexico, the direct costs of diabetes were estimated at approx-
imately US $1.16 billion (15 billion Mexican pesos [MXP]) in
2006, and these ﬁgures have steadily increased [4]. Estimates
suggest that diabetes-related complications can substantially
increase patient costs in Mexico [4]. As noted in a recent
consensus statement from the Latin American Diabetes Associ-
ation, the Latin American health care system has historically
focused on the treatment of acute health conditions, primarilyociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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become more common in Latin America, payers and clinicians
will face challenges unique to this region in helping patients
achieve health-related goals.
Maintaining near-normal blood glucose levels has been
shown to improve key T2DM-related outcomes [6]. The Latin
American Diabetes Association and the Institute of Mexican
Social Security (IMSS) recommend maintaining a glycated hemo-
globin (HbA1c) level of less than 7.0%, blood pressure of less than
or equal to 130/80 mmHg, and low-density lipoprotein cholesterol
(LDL-C) level of less than 100 mg/dL in most patients [5,7],
consistent with the recommendations of the American Diabetes
Association [8]. In addition, guidelines emphasize the importance
of weight loss/control in T2DM management, reﬂecting acknowl-
edgement of the detrimental effects of excess weight on health
outcomes [5,7,8].
Many patients do not meet or maintain glycemic goals with
available treatments [9,10]. According to data from the 2006
Mexican National Nutrition Survey, only 5.3% of the patients
with T2DM were found to have an HbA1c level of 7.0% or less
despite treatment [11]. Notably, more than half had an HbA1c
≥11.0%. Similarly, data indicate widespread failure to meet blood
pressure and lipid goals in Mexico. In 2006, for example, approx-
imately one-third of the Mexican population had a systolic blood
pressure (SBP) of ≥140 mmHg and approximately 75% had LDL-C
≥100 mg/dL [12,13]. Moreover, two-thirds were classiﬁed as being
overweight or obese [14].
Canagliﬂozin is an agent that inhibits sodium glucose co-
transporter 2 (SGLT2), which is approved in numerous countries
[15], including Mexico, for the treatment of adults with T2DM
[16,17]; the efﬁcacy and safety of canagliﬂozin have been dem-
onstrated in phase III clinical trials of up to 2 years in a broad
range of patients with T2DM [18–27]. Canagliﬂozin leads to
inhibition of glucose reabsorption and increased urinary glucose
excretion, thereby reducing blood glucose, body weight (predom-
inantly due to fat loss), and SBP (from weight loss and mild
osmotic diuresis), with a low risk of hypoglycemia, which can be
a limiting factor for achieving treatment goals [28]. This insulin-
independent mechanism differentiates canagliﬂozin from other
classes of antihyperglycemic agents (AHAs), such as dipeptidyl
peptidase-4 inhibitors, including sitagliptin, which act directly on
β cells to lower blood glucose.
The present analysis is based on results from a clinical
study that directly compared canagliﬂozin 300 and 100 mg
versus sitagliptin 100 mg in dual therapy with metformin in
patients with T2DM [20]. This was a randomized, double-blind,
four-arm, parallel-group, placebo- and active-controlled, phase
III study. Change in HbA1c from baseline to week 52 was a key
end point, with a hypothesis that canagliﬂozin 300 mg or both
doses would demonstrate noninferiority in lowering HbA1c
versus sitagliptin 100 mg. In the clinical study, canagliﬂozin
300 mg demonstrated superiority and canagliﬂozin 100 mg
demonstrated noninferiority compared with sitagliptin 100 mg
in lowering HbA1c at 52 weeks (–0.88%, –0.73%, and –0.73%,
respectively). Canagliﬂozin 300 and 100 mg also provided
reductions compared with sitagliptin 100 mg in body weight
(–4.2%, –3.8%, and –1.3%, respectively) and SBP (–4.7, –3.5, and
–0.7 mmHg, respectively). Both doses of canagliﬂozin were
generally well tolerated. Although the incidences of adverse
events (AEs) potentially related to the mechanism of SGLT2
inhibition, such as male and female genital mycotic infections
(e.g., yeast infections), osmotic diuresis–related AEs (e.g., polla-
kiuria, polyuria, and nocturia), and volume depletion–related
AEs (e.g., orthostatic hypotension and postural dizziness), were
higher with both canagliﬂozin doses than with sitagliptin in the
study, AE-related discontinuation rates were similar across
treatment groups.Because T2DM is chronic and progressive, the costs and
health beneﬁts of interventions are fully realized only over long
time horizons. Ideally, therefore, cost-effectiveness analyses of
T2DM interventions would be informed by long-term, natural-
istic, randomized clinical trials [29,30]. Clinical trials of sufﬁcient
duration, however, are rarely (if ever) available at the time that
initial coverage decisions are made. As such, economic computer
modeling that extrapolates the available clinical trial data to
long-term health economic outcomes has been widely accepted
as a way to assess the cost-effectiveness of alternative T2DM
treatment strategies [29,30].
Given the growing economic burden of T2DM in Latin America
and speciﬁcally in Mexico, cost-effectiveness evaluations can
inform decisions about the efﬁcient allocation of limited health
care resources. Mexico’s independent health technology assess-
ment body, Centro Nacional de Excelencia Tecnológica en Salud,
encourages the use of cost-effectiveness analysis and states a
willingness-to-pay (WTP) threshold of 1 times the gross domestic
product (GDP) per capita as “very cost-effective” (MXP 141,120 or
US $10,500; exchange rate as of September 26, 2014 of US $1 ¼
MXP 13.44) [31]. Centro Nacional de Excelencia Tecnológica en
Salud further states that for treatments with costs per QALY
gained of ≥1 and ≤3 times the GDP per capita, a detailed analysis
should be performed; those with costs per QALY gained of >3
times the GDP per capita should not be considered “cost-effec-
tive” [32,33]. These WTP thresholds are in line with those
recommended by the World Health Organization [34].
Comparing diabetes treatment alternatives over the long term
from the perspective of the Mexican health care system is
necessary to direct resources in the most efﬁcient manner,
enabling better patient outcomes from available resources. In
this study, the cost-effectiveness of adding canagliﬂozin 300 or
100 mg versus sitagliptin 100 mg in patients with T2DM inad-
equately controlled on metformin monotherapy was determined
using the 1 and 3 times the GDP per-capita thresholds. The
incremental cost-effectiveness ratios (ICERs) were estimated
using a validated microsimulation model, Economic and Health
Outcomes (ECHO)-T2DM, with local cost data [35].Methods
Model Overview and Simulation Description
ECHO-T2DM is a stochastic microsimulation (patient-level) cost-
effectiveness model of the treatment of T2DM (see Fig. 1 for a
diagrammatic overview) [35]. The physiology of T2DM is captured
using Markov health states for microvascular and macrovascular
complications and death. The cycle length is 1 year, and the time
horizon is deﬁned by the user. ECHO-T2DM accounts explicitly for
both ﬁrst-order uncertainty (associated with interpatient varia-
bility) and second-order uncertainty (uncertainty regarding the
true value of the underlying parameters) and is programmed in R
using user-friendly front- and back-end Excel interfaces. Because
of space limitations, technical details including a conceptual
walk through, parameterization of macrovascular and micro-
vascular complications (i.e., chronic kidney disease, neuropathy,
retinopathy), and parameters related to uncertainty and hetero-
geneity can be found in the Appendix in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2014.12.017.
Cohorts of hypothetical patients are generated at the start of
the simulation. Each patient is deﬁned by age, sex, disease
duration, HbA1c, biomarker values, smoking status, and preexist-
ing health conditions (micro- and macrovascular disease). Bio-
marker values at the individual level tend to be correlated; for
example, the clustering of poor glycemic control, hypertension,
dyslipidemia, and overweight affected 41.6% of the Mexican
Fig. 1 – ECHO-T2DM model. BDR, background diabetic retinopathy; CHF, congestive heart failure; CVD, cardiovascular disease;
ECHO-T2DM, Economic and Health Outcomes model of type 2 diabetes mellitus; eGFR, estimated glomerular ﬁltration rate; HDL-C,
high-density lipoprotein cholesterol; IHD, ischemic heart disease; LDL-C, low-density lipoprotein cholesterol; LEA, lower extremity
amputation; ME, macular edema; MI, myocardial infarction; PDR, proliferative diabetic retinopathy; PVD, peripheral vascular
disease; QALY, quality-adjusted life-year; SBP, systolic blood pressure; TGR, triglycerides; UKPDS, UK Prospective Diabetes Study.
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ual patient’s biomarkers, accounting for key correlations between
the biomarkers themselves (and age) explicitly [37].ECHO-T2DM includes a comprehensive set of health compli-
cations. Microvascular health states reﬂect increasing severity of
chronic kidney disease (tracked by both the albumin-to-
V A L U E I N H E A L T H R E G I O N A L I S S U E S 8 C ( 2 0 1 5 ) 8 – 1 9 11creatinine ratio and the estimated glomerular ﬁltration rate
[eGFR]), retinopathy, and neuropathy (see Appendix Sections
2.1, 2.2, and 2.3 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2014.12.017). HbA1c- and T2DM-duration–
speciﬁc progression rates steer transition between the different
health states, and are largely taken from previous modeling work
[38–40]. Macrovascular health states consist of ischemic heart
disease, myocardial infarction, stroke, and congestive heart fail-
ure; myocardial infarction and stroke can occur multiple times.
ECHO-T2DM includes four different sets of macrovascular risk
equations, including both the new and the original UK Prospec-
tive Diabetes Study risk functions [41,42], the Action in Diabetes
and Vascular Disease: Preterax and Diamicron Modiﬁed-release
Controlled Evaluation (ADVANCE) risk function, and the Swedish
National Diabetes Registry risk function [43]. The new UK Pro-
spective Diabetes Study risk functions (UK Prospective Diabetes
Study 82 [42]) were used in this application to model macro-
vascular (and mortality) risks because they include separate risks
for second events for some complications and because the
developers suggest they do not have the tendency to overpredict
risks, as was seen with the original set (likely due, in part, to the
doubling of follow-up to >20 years). Mortality consists of four
equations covering general mortality; case fatality in the year
following a primary event (e.g., stroke); excess mortality risk
related to a history of diabetes complications such as myocardial
infarction, stroke, and end-stage renal disease; and excess mor-
tality risk in the years following an event [42].
The algorithm for drug intensiﬁcation in ECHO-T2DM is
designed to maintain HbA1c target values, including an option
for contraindication and discontinuation due to health conditions
(including, e.g., end-stage renal disease and macrovascular dis-
ease). Failure to achieve the glycemic target can lead to dose
increases (if available) or the addition of new agents (previous
agents can be continued or discontinued at failure).
Patient biomarker values (i.e., HbA1c, SBP, body mass index
[BMI], and lipids) are updated each cycle and incorporate annual-
ized drug-speciﬁc “drifts,” which capture deterioration in these
biomarkers over time, net of the treatment effects [6,44].
To account for the observed changes in the efﬁcacy of agents
with SGLT2 activity (such as canagliﬂozin) with declining eGFR,
HbA1c-, SBP-, and BMI-lowering can be adjusted. Speciﬁcally
in these analyses, when eGFR was simulated to drop below
60 mL/min/1.73 m2, the treatment effects of canagliﬂozin on
these biomarkers were adjusted to correspond to estimates
obtained from a pooled analysis of subjects in the clinical
trial program with moderate renal impairment (eGFR Z45 and
o60 mL/min/1.73 m2) [45]. Treatment with canagliﬂozin (though
not with sitagliptin) was discontinued if eGFR fell below
30 mL/min/1.73 m2 per the Mexican label at the time of the
analysis [17].
Although neither canagliﬂozin nor sitagliptin is associated
with an increased risk of hypoglycemia on the basis of their
mechanism of action [16,46], nonsevere symptomatic hypoglyce-
mic episodes and severe hypoglycemic episodes (i.e., those
requiring third-party assistance) were modeled using data from
the clinical study [20]. Data from the clinical study [20] were also
used as model inputs for AEs potentially related to the mecha-
nism of action of SGLT2 inhibition, including male and female
genital mycotic infections (i.e., yeast infections) [47], lower and
upper urinary tract infections [48], and osmotic diuresis–related
AEs and volume depletion–related AEs [49]. The risk of volume
depletion–related AEs was adjusted using the pooled renal
impairment data for those with an eGFR of less than 60 mL/
min/1.73 m2, for those aged 75 years or older, and for those on a
loop diuretic [50]. Note that AEs potentially associated with the
mechanism of action of dipeptidyl peptidase-4 inhibitors (e.g.,
pancreatitis [51]) were not modeled.Antihypertension and antidyslipidemia treatment algorithms
based on meeting blood pressure and lipid targets can also be
applied. The hypothetical patients in the present analysis were
treated to an SBP target of 140 mmHg and an LDL-C target of 100
mg/dL using a treatment algorithm consistent with Mexican
guidelines [52], with treatment effect data obtained from the
literature [53–55].
Costs can be assigned for treatment interventions and AEs,
initial-year medical events, and resources related to the disease
history and follow-up. Patient preferences for health are captured
using quality-adjusted life-year (QALY) disutility weights (i.e.,
decrements in quality of life associated with a negative impact
of particular health states) for patients’ demographic character-
istics (including age and sex), clinical characteristics (including
disease duration and BMI), the presence of individual micro-
vascular and macrovascular complications, hypoglycemia,
and AEs.
Outcomes include the cumulative incidence of each type of
health outcome and relative risk reductions in microvascular and
macrovascular events, life-years and QALYs, biomarker evolution
curves, and cost and cost-effectiveness metrics.
The external (predictive) validity of ECHO-T2DM has been
assessed by replicating the design of a number of clinical trials
and simulating various outcomes over the respective time hori-
zons, and then comparing model predictions with the observed
trial results (see Willis et al. [35] for a full description). Results
demonstrated that ECHO-T2DM simulated patient outcomes for
various microvascular and macrovascular outcomes observed in
important clinical trials with an accuracy that is consistent with
that of other well-accepted models.
Simulation Parameters
In the base case, a total of 1000 cohorts of 2000 hypothetical
patients with T2DM (i.e., 2 million unique hypothetical patients)
were randomly generated and simulated over 20 years to ensure
that long-term costs and beneﬁts of treatment intervention in
chronic and progressive T2DM were captured. The large number
of patients per cohort ensures that the ﬁrst-order uncertainty is
small, and the large number of cohorts ensures that the second-
order uncertainty is captured. All future costs and health beneﬁts
(i.e., life-years, QALYs) were discounted at 5% per Centro Nacio-
nal de Excelencia Tecnológica en Salud guidelines [56]. In this
analysis, cost-effectiveness was assessed using the WTP thresh-
olds of 1 times GDP per capita (i.e., MXP 141,200/QALY) and 3
times GDP per capita (i.e., MXP 423,600/QALY) suggested by the
Mexican government and the World Health Organization [57].
Note that an ICER below the more conservative threshold of 1
times GDP per QALY is considered to be very cost-effective per
the World Health Organization.
Patient Proﬁles
Baseline demographic and disease characteristics reﬂecting the
distribution of those from the head-to-head study of canagliﬂozin
versus sitagliptin described above [20] were randomly generated
for each hypothetical patient (Table 1).
Treatment Comparisons and Algorithm
Two treatment comparisons were simulated: (1) canagliﬂozin
300 mg versus sitagliptin 100 mg and (2) canagliﬂozin 100 mg
versus sitagliptin 100 mg added to maximally tolerated metfor-
min. Treatment effects for canagliﬂozin 300 and 100 mg and
sitagliptin 100 mg were obtained from the clinical trial data
(Table 1; see Appendix Table 5 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2014.12.017). Treatment effects
(i.e., HbA1c, weight gain) and hypoglycemia incidences for basal
Table 1 – Key baseline patient characteristics and clinical inputs for canagliﬂozin 300 and 100 mg and
sitagliptin 100 mg.*
Characteristic† Overall population total (N ¼ 1284) Latin American sample total (N ¼ 240)
Age (y) 55.4  9.4 54.8  9.2
Sex (%)
Male 47.1 36.1
Female 52.9 63.9
Duration of T2DM (y) 6.9  5.3 7.7  5.6
HbA1c (%) 7.9  0.9 7.9  0.9
Total cholesterol (mg/dL) 189.8  39.9 196.2  35.5
LDL-C (mg/dL) 107.9  33.6 112.3  30.5
HDL-C (mg/dL) 45.3  11.2 45.2  11.4
SBP (mmHg) 128.2  13.0 124.4  13.4
BMI (kg/m2) 31.8  6.2 30.7  5.5
Current smoker (%) 12.5 7.5
Atrial ﬁbrillation (%) 0.8 0
Background diabetic retinopathy (%) 6.6 2.9
Macular edema (%) 0.1 0
Proliferative diabetic retinopathy (%) 0.1 0
Microalbuminuria (%) 0.5 1.1
Macroalbuminuria (%) 0.4 0
Symptomatic neuropathy (%) 2.6 0.4
Treatment effects‡ Overall population Latin American sample
CANA 300 mg
(n ¼ 367)
CANA 100 mg
(n ¼ 368)
SITA 100 mg
(n ¼ 366)
CANA 300 mg
(n ¼ 79)
CANA 100 mg
(n ¼ 80)
SITA 100 mg
(n ¼ 81)
HbA1c (%) –0.88 –0.73 –0.73 –0.94 –0.95 –0.73
Total cholesterol (mg/dL) 7.08 6.11 3.37 8.42 3.63 11.23
LDL-C (mg/dL) 4.40 4.33 3.12 5.63 4.25 9.29
HDL-C (mg/dL) 5.51 4.50 2.36 5.56 5.13 2.32
Triglycerides (mg/dL) –16.61 –11.05 –13.51 –9.22 –27.50 –6.36
SBP (mmHg) –4.65 –3.53 –0.66 –4.36 –3.61 –0.40
BMI (kg/m2)§ –1.35 –1.22 –0.45 –1.31 –1.11 –0.22
Annual “drift” in HbA1c (%)
|| 0.14 0.14 0.14 0.14 0.14 0.14
Annual “drift” in SBP (mmHg)|| 0.3 0.3 0.3 0.3 0.3 0.3
Annual “drift” in lipid
parameters (mg/dL)||
0.03 0.03 0.03 0.03 0.03 0.03
AEs, per patient-year of
exposure (%)
Severe hypoglycemia 0 0.3 0.3 0 1.4 1.4
Nonsevere symptomatic
hypoglycemia
8.5 8.8 4.4 15.8 27.1 9.7
Volume depletion–related
AEs
1.3 1.3 2.7 1.4 1.4 1.4
Osmotic diuresis–related AEs 4.1 8.5 1.0 4.3 6.6 1.4
Male genital mycotic
infection
2.7 5.9 1.3 10.6 16.0 2.8
Female genital mycotic
infection
11.1 12.9 3.0 19.0 15.8 2.4
Lower UTI 7.4 9.3 7.8 12.6 17.2 11.8
Upper UTI 0.3 0.6 0.3 0 0 1.3
AE, adverse event; BMI, body mass index; CANA, canagliﬂozin; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation; SITA, sitagliptin; T2DM, type 2 diabetes
mellitus; UTI, urinary tract infection.
* All data are from the clinical study unless otherwise noted [20].
† Data are mean  SD from baseline to week 52 (modiﬁed intent-to-treat) unless otherwise indicated.
‡ Data are least squares mean changes from baseline to week 52 (modiﬁed intent-to-treat) unless otherwise indicated.
§ Some weight loss was seen in the sitagliptin arm because all patients followed a regimen of diet and exercise in addition to pharmacologic
treatment (a requirement in registration trials in diabetes).
|| Sourced from the literature [6,44].
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Table 2 – AHA treatment intensiﬁcation algorithm.
 Hypothetical patients entered the model uncontrolled on
background metformin and were assigned to treatment with
canagliﬂozin 300 or 100 mg or sitagliptin 100 mg.
 Patients meeting the HbA1c target level of o7.0% continued on
their assigned treatment.
 Patients were discontinued from treatment with canagliﬂozin
or sitagliptin because of AEs in the ﬁrst cycle at the rates
observed in the clinical trial. Otherwise, patients remained on
their assigned treatment unless the HbA1c level was Z7.0% or
eGFR was o30 mL/min/1.73 m2 (eGFR threshold applied only to
canagliﬂozin).
 When the HbA1c level was Z7.0%, AHA treatment was
intensiﬁed by adding basal insulin (i.e., neutral protamine
Hagedorn [NPH]) insulin), initially at 10 IU/d; the dose could be
titrated up to 60 IU/d as needed to maintain HbA1c o7.0%.
 When the HbA1c level was Z7.0% at the maximum dose of
basal insulin, prandial insulin was added (and titrated as
required to maintain control up to 200 IU/d).
AE, adverse event; AHA, antihyperglycemic agent; eGFR, estimated
glomerular ﬁltration rate; HbA1c, glycated hemoglobin; NPH, neu-
tral protamine Hagedorn.
Table 3 – Event-year and state costs and QALY utility we
Clinical event Event-year c
(MXP)
Macrovascular
Ischemic heart disease 39,816
Myocardial infarction 172,872
Congestive heart failure 27,469
Stroke 54,835
Peripheral vascular disease 26,290
Microvascular
Microalbuminuria 723
Macroalbuminuria 723
eGFR o15 mL/min/1.73 m2 (1st year) 0
eGFR o15 mL/min/1.73 m2 (end-stage renal
disease)
179,003
Macular edema 1,307
Proliferative retinopathy 5,546
Blindness in both eyes 14,231
Symptomatic neuropathy 15,960
Diabetic foot ulcer 7,745
Lower extremity amputation 74,373
Hypoglycemia
Nonsevere symptomatic hypoglycemic event 0
Severe hypoglycemic event 2,651
Overweight/obesity
For each 1 kg/m2 over 25 kg/m2 NA
AEs
Lower UTI (male) 925
Lower UTI (female) 881
Upper UTI (male) 6,018
Upper UTI (female) 5,883
GMI (male) 6,348
GMI (female) 1,518
Volume depletion–related AEs 2,080
Osmotic diuresis–related AEs 1,418
AE, adverse event; GMI, genital mycotic infection; MXP, Mexican peso; N
infection.
* Event costs are associated with management of the acute episode and
† Assumed equal to the value of a nonsevere symptomatic hypoglycemi
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Details of the AHA treatment intensiﬁcation algorithm applied in
these simulations are given in Table 2.Costs
The costs of myocardial infarction, stroke, and lower extremity
amputation were sourced from the diagnostic-related groups
issued by the IMSS in 2012 (Table 3). Costs for macular edema,
proliferative retinopathy, and blindness were obtained from the
Mexican health care administration agency, the Instituto de
Seguridad y Servicios Sociales de los Trabajadores del Estado,
the costing table, and the IMSS. Costs for end-stage renal disease
were obtained from literature searches of studies and articles
related to diabetes [61]. The remaining cost inputs were obtained
from interviews that were conducted with clinicians in public
Mexican hospitals to assess how most patients would be treated
and mapping to the Instituto de Seguridad y Servicios Sociales de
los Trabajadores del Estado costing table [62,63]. Resource uti-
lization was matched with cost data using several sources as
follows. Costs for laboratory studies, physician visits, hospital-
izations, intensive care, and emergency visits were matched to
those from established sources [64,65]. Unit costs of medications
used to treat comorbidities were sourced from the IMSS and theight inputs.
ost* State, annualized cost
(MXP)
QALY utility
weights
16,898 –0.028 [38]
16,898 –0.028 [38]
11,991 –0.028 [38]
16,313 –0.115 [38]
23,669 –0.061 [38]
41 0 [38]
41 –0.048 [38]
NA –0.175 [38]
170,923 –0.175 [38]
652 NA
652 0 [38]
652 –0.057 [38]
7,980 –0.084 [38]
NA –0.17 [38]
NA –0.272 [38]
NA –0.005 [69]
NA –0.06 [69]
NA –0.0171 [72]
NA –0.00123 [70]
NA –0.00123 [70]
NA –0.00729 [70]
NA –0.00729 [70]
NA –0.0046 [70]
NA –0.0046 [70]
NA –0.005 [69]†
NA –0.005 [71]
A, not applicable; QALY, quality-adjusted life-year; UTI, urinary tract
any subsequent care in the ﬁrst year.
c event.
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ﬂozin 300 and 100 mg and sitagliptin 100 mg were speciﬁed as
MXP 27.11, MXP 27.11, and MXP 26.07 per day, respectively. These
prices were sourced from a local retail pharmacy (i.e., Walmart)
because they are not yet widely available in the institutional
formularies of the public sector, and represent the cost that
would be paid out of pocket. All costs were converted to 2012 MXP
using the National Consumer Price Index released by the Mexican
government [68].
QALY Disutility
QALY disutility weights are given in Table 3. Because detailed
utility studies do not exist for diabetes in the Mexican population,
utility values were obtained from established sources based on
other T2DM populations. Values assigned to microvascular and
macrovascular complications were obtained from a widely used
source in the economic modeling of T2DM [38], which used
multivariate regression techniques to isolate the unique contri-
bution of each health outcome. The study did not estimate
disutility estimates for hypoglycemia and AEs. Disutilities for
nonsevere symptomatic and severe hypoglycemic events were
sourced from a recent time trade-off study in 1603 individuals
with T2DM [69]. Disutility values for urinary tract infections and
genital mycotic infections were taken from a new time trade-off
study in T2DM that was, in large part, performed to provide
estimates for these selected AEs potentially related to SGLT2
inhibition [70]. The disutility for the group of osmotic diuresis–
related AEs was derived from a study of symptoms associated
with overactive bladder in the general population [71]. The
disutility associated with volume depletion–related AEs was
assumed to be equal to that of nonsevere symptomatic hypo-
glycemia because symptoms of these events are somewhat
similar. The estimate of the disutility-associated weight gain of
1 BMI unit (kg/m2; applied only when the BMI was 425 kg/m2)
was obtained from the most recent article investigating this issue
[72].
Sensitivity Analyses
One-way sensitivity analyses were conducted to explore the
robustness of the base-case results to scenarios potentially more
reﬂective of Mexico and to key assumptions related to the proﬁle
of canagliﬂozin. These sensitivity analyses are described in
logical groups:1. Clinical characteristics, efﬁcacy, and AE rates: set to those
obtained from a post hoc subgroup analysis of subjects from
Latin America in the clinical trial (SA1; see Table 1, Latin
American sample).2. Treatment rules: AHA treatment intensiﬁcation threshold set
to 8.0% (vs. the base-case assumption of 7.0%; SA2), a level
that may be more reﬂective of Mexico.3. Time horizon: shorter time horizon of 10 years (SA3) and
longer time horizons of 30 years (SA4) and 40 years (SA5).4. Disutility associated with weight change: more conservative
disutility estimate associated with weight gain in individuals
with a BMI of more than 25 kg/m2 (0.0061 per unit gained
above 25 kg/m2) [38] (SA6).5. AEs potentially related to SGLT2 inhibition: double associated
costs (SA7); double associated QALYs (SA8).
Note that the number of hypothetical patients simulated in
each of the 1000 cohorts was 1000 for the sensitivity analyses (i.e.,
1 million hypothetical patients). This has been shown to be of
sufﬁcient size to generate stable results (data available on
request).Outcomes Reporting and Statistical Analyses
The cumulative incidence rates for each type of microvascular
and macrovascular outcome, event rates for AEs, their associated
costs (both total and disaggregated), and mean life-years and
QALYs experienced over the simulation period were calculated
for each treatment arm. Relative risk reductions for canagliﬂozin
versus sitagliptin were generated for microvascular and macro-
vascular complications; hazard ratios for the AEs and differences
for the costs, life-years, and QALYs were also generated. The
ICERs were computed, as were scatterplots of cost-effectiveness
planes and cost-effectiveness acceptability curves.Results
Base-Case Analyses
Canagliﬂozin 300 and 100 mg were associated with improved life
expectancy and QALY gains of 0.16 and 0.06, respectively, relative
to sitagliptin 100 mg (Table 4). The incremental lifetime costs per
patient associated with adding canagliﬂozin 300 or 100 mg for
patients with uncontrolled HbA1c on a background of metformin
were estimated at MXP 1797 and MXP 7262, respectively. The
resulting ICERs of MXP 11,210 and MXP 128,883 for canagliﬂozin
300 and 100 mg versus sitagliptin 100 mg, respectively, are below
the WTP threshold of 1 times the GDP per capita for a QALY
gained, suggesting that both doses are very cost-effective (Table 4).
Because the hypothetical patients were treated with rescue
medications to meet HbA1c, SBP, and lipid goals, differences in
key biomarkers driving event risks for macrovascular and espe-
cially microvascular events were effectively minimized, with the
consequence that cost offsets and avoided QALY losses related to
these complications were smaller than would have been the case
without strict treatment-to-goal rescue medication (see base case
results for cumulative incidences and relative risk reductions in
Supplemental Table 1 in Supplemental Material found at http://dx.
doi.org/10.1016/j.jval.2014.12.017 and associated costs in Table 4).
The greater initial HbA1c lowering for canagliﬂozin 300 mg
translated into a reduced need for insulin rescue therapy, which
resulted in cost offsets of MXP –2686 in overall insulin therapy use
associated with canagliﬂozin 300 mg relative to sitagliptin 100 mg.
In the simulation of canagliﬂozin 100 mg versus sitagliptin 100 mg,
estimated insulin costs were higher in the canagliﬂozin arm,
owing largely to the discontinuation of canagliﬂozin (but not
sitagliptin) if an eGFR of less than 30 mL/min/1.73 m2 was
eventually reached. In addition, decreases in SBP contributed to
decreased costs for the treatment of hypertension with canagli-
ﬂozin 300 and 100 mg (MXP –1154 and –947, respectively).
As previously mentioned, both doses of canagliﬂozin gener-
ated QALY gains versus sitagliptin. The largest drivers of QALY
differences were lower disutility associated with overweight/
obesity (–0.129 and –0.097, respectively) and with mortality
(–0.017 and –0.012, respectively; see Supplemental Table 2 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.12.017). For canagliﬂozin 300 mg, less need for insulin rescue
therapy also contributed to reduced disutility associated with
hypoglycemic events. For canagliﬂozin 100 mg, the difference in
the estimated disutilities associated with hypoglycemia favored
sitagliptin, in part owing to the discontinuation of canagliﬂozin
and start of insulin for patients who reached an eGFR of less than
30 mL/min/1.73 m2. This result may be compounded, moreover,
by the likely spurious differences observed in rates of hypogly-
cemia between canagliﬂozin 100 mg and sitagliptin 100 mg in the
clinical trial; both canagliﬂozin and sitagliptin have mechanisms
of action that have been shown to not independently increase the
risk of hypoglycemia [16,46]. The disutilities associated with AEs
Table 4 – Base case, costs of complications and AEs, average costs, and beneﬁts per person, over 20 y (modeled).
Outcome parameter CANA
300 mg
SITA
100 mg
Difference CANA
100 mg
SITA
100 mg
Difference
Costs (MXP), discounted
Macrovascular
Myocardial infarction 24,951 26,906 –955 24,428 24,787 –540
Ischemic heart disease 13,111 13,611 –500 12,924 13,306 –382
Congestive heart failure 3,720 3,915 –195 3,738 3,884 –146
Stroke 4,220 4,436 –215 4,121 4,285 –163
Microvascular
Retinopathy 9,455 9,461 –5 9,461 9,449 13
Nephropathy 1,528 1,539 –12 1,528 1,535 –7
Neuropathy 35,054 35,111 –58 35,116 35,021 94
AHA
Oral agents 155,433 150,781 4,652 152,916 150,573 2,343
Insulin 56,242 58,927 –2,686 60,499 58,837 1,662
Prescription treatment
Hypoglycemia 357 428 –71 464 445 19
AEs 3,675 2,439 1,236 5,657 2,439 3,218
Hypertension 3,495 4,649 –1,154 3,699 4,645 –947
Dyslipidemia 18,846 17,086 1,760 19,215 17,117 2,099
Total costs (MXP) 330,087 328,290 1,797 333,587 326,324 7,262
Health indicators, discounted
Life-years 10.66 10.64 0.02 10.64 10.63 0.02
QALYs 6.35 6.19 0.16 6.23 6.18 0.06
Survival (%)* 56.8 56.4 0.4 56.5 56.2 0.3
Cost per QALY (MXP) – – 11,210 – – 128,883
AE, adverse event; AHA, antihyperglycemic agent; CANA, canagliﬂozin; MXP, Mexican peso; QALY, quality-adjusted life-year; SITA, sitagliptin.
* Percentage alive at simulation end.
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sitagliptin, but their impact was small in magnitude (0.003 and
0.006 for canagliﬂozin 300 and 100 mg vs. sitagliptin 100 mg,
respectively).
The effect of parameter uncertainty on outcomes is illustrated
in the scatterplot of the incremental costs and QALYs from each
of the 1000 cohorts. Canagliﬂozin 300 mg was associated with
greater QALYs in all 1000 simulations (northeast and southeast
quadrants; Fig. 2A), and nearly half of the cohort replications had
lower costs as well (southeast quadrant; Fig. 2A). Canagliﬂozin
100 mg was associated with more QALYs than sitagliptin 100 mg
in all but 1 of the 1000 cohort replications (Fig. 2B). Canagliﬂozin
100 mg was also associated with greater costs in most of the
replications, though in a minority of cases it was associated with
greater QALYs and lower costs (Fig. 2B). These scatterplots
indicate a high degree of conﬁdence that canagliﬂozin 300 mg
is very cost-effective versus sitagliptin 100 mg, which is depicted
graphically in Fig. 2C. The likelihood that canagliﬂozin is cost-
effective versus sitagliptin 100 mg naturally increases as the WTP
increases (i.e., gains in QALYs become increasingly rewarded),
reaching approximately 95% for canagliﬂozin 300 mg at both
speciﬁed WTP thresholds. Canagliﬂozin 100 mg has an approx-
imately 65% probability of being cost-effective versus sitagliptin
100 mg at the 3 times the GDP per-capita threshold versus
approximately 50% probability of being very cost-effective at
the more conservative WTP threshold (Fig. 2C). The probability
that canagliﬂozin is cost saving is indicated by the probability at a
WTP of 0 (the Y axis), and is approximately 37% for the 300-mg
dose and approximately 10% for the 100-mg dose.
Sensitivity Analyses
Findings from the sensitivity analyses generally support the ﬁndings
of the base case that canagliﬂozin is cost-effective versus sitagliptin.In fact, QALY gains for canagliﬂozin 300 and 100 mg versus
sitagliptin 100 mg increased to 0.19 and 0.27, respectively, from
0.16 and 0.06 in the base case, respectively, in the case in which the
Latin American subsample data from the clinical study were used to
deﬁne clinical characteristics, efﬁcacy, and AE rates. Total cost
offsets were MXP –2256 and –8088 with canagliﬂozin 300 and
100 mg, respectively. Both canagliﬂozin doses dominated sitagliptin
100 mg (i.e., lower costs and higher QALYs) in this scenario (Table 5).
Using the less stringent HbA1c treatment target of less than 8.0%,
QALY gains for canagliﬂozin 300 and 100 mg versus sitagliptin 100
mg were 0.14 and 0.08, respectively, with total cost increases of MXP
3477 and 6521, respectively. In this scenario, both canagliﬂozin 300
and 100 mg were very cost-effective (Table 5).
When the time horizon was shortened to 10 years, QALY gains
were 0.11 and 0.06 for canagliﬂozin 300 and 100 mg versus
sitagliptin 100 mg, respectively, with total cost increases of MXP
1592 and 4582, respectively. QALY gains were 0.17 and 0.04 for
canagliﬂozin 300 and 100 mg versus sitagliptin 100 mg, respec-
tively, over 30 years, and 0.18 and 0.05, respectively, over 40 years.
Cost increases were seen with canagliﬂozin 300 and 100 mg
versus sitagliptin 100 mg of MXP 2076 and 9084, respectively, over
30 years, and MXP 2483 and 9508, respectively, over 40 years. In
each of these analyses, canagliﬂozin 300 mg was very cost-
effective and canagliﬂozin 100 mg was cost-effective at the
WTP threshold of 3 times the GDP per capita (Table 5).
Using a more conservative disutility for overweight/obesity,
treatment with canagliﬂozin 300 mg versus sitagliptin 100 mg
resulted in a QALY gain of 0.08 (smaller compared with the base
case) and a cost increase of MXP 1797 for canagliﬂozin 300 mg,
compared with a small decrease in QALYs of –0.01 and a cost
increase of MXP 7262 with canagliﬂozin 100 mg versus sitagliptin
100 mg. Thus, in this conservative scenario, canagliﬂozin 100 mg
was dominated by sitagliptin 100 mg, but canagliﬂozin 300 mg
remained very cost-effective (Table 5).
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Fig. 2 – Cost-effectiveness planes for (A) CANA 300 mg and
(B) CANA 100 mg* and (C) cost-effectiveness acceptability
curves for CANA 300 and 100 mg over time. CANA,
canagliﬂozin; MXP, Mexican peso; QALY, quality-adjusted
life-year; WTP, willingness to pay. *Open circles represent
the mean value across cohorts.
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tially related to the SGLT2 mechanism of action, canagliﬂozin 300
and 100 mg showed QALY gains of 0.16 and 0.05, respectively,
relative to sitagliptin 100 mg; costs were higher by MXP 2964 and
10,353, respectively. When the QALYs associated with AEs poten-
tially related to the SGLT2 mechanism of action were doubled,
canagliﬂozin 300 and 100 mg versus sitagliptin 100 mg resulted in
QALY gains of 0.16 and 0.05, respectively, and cost increases of
MXP 1729 and 7138, respectively. Canagliﬂozin 300 mg was verycost-effective when either costs or quality of life associated with
SGLT2-related AEs was doubled; canagliﬂozin 100 mg was cost-
effective at the WTP threshold of 3 times the GDP per capita in
these analyses (Table 5).Discussion and Conclusions
Economic simulations in the Mexican setting based on the
52-week clinical study data of patients with T2DM on background
metformin suggest that the use of canagliﬂozin 300 and 100 mg is
associated with improved health outcomes, associated QALY
gains, and a relatively marginal increase in total costs relative
to sitagliptin 100 mg. Both canagliﬂozin doses were found to be
cost-effective for patients with T2DM in Mexico, even when
considering the most conservative WTP threshold suggested by
the Mexican government. The base-case cost-effectiveness esti-
mates of MXP 11,210/QALY gained (US $834) and MXP 128,883/
QALY gained (US $9590) for canagliﬂozin 300 and 100 mg,
respectively, fell below this conservative threshold, suggesting
that both doses were very cost-effective.
Note that the ICER for canagliﬂozin 100 mg versus sitagliptin
100 mg is inﬂuenced by the difference observed in the inci-
dence of nonsevere symptomatic hypoglycemia with canagli-
ﬂozin 100 mg versus sitagliptin 100 mg in the clinical trial. As
noted above, however, both agents have a low inherent risk of
hypoglycemia [16,46] and the observed difference is likely
spurious. Sensitivity analyses modeling equal rates of non-
severe symptomatic hypoglycemia with canagliﬂozin 100 mg
and sitagliptin 100 mg were performed in various scenarios,
and, indeed, lower ICERs for canagliﬂozin 100 mg were esti-
mated (data on ﬁle).
All ICERs generated for canagliﬂozin 300 mg in the sensitivity
analyses fell below the very cost-effective WTP threshold. ICERs
generated for canagliﬂozin 100 mg were very cost-effective,
except in the sensitivity analyses related to the unlikely scenarios
of a doubling of costs or QALYs for AEs potentially associated
with the SGLT2 mechanism of action or analyses over longer time
horizons (30 and 40 years); however, these were cost-effective at
the WTP threshold of 3 times the GDP per capita. The increase in
ICERs seen over longer time horizons with canagliﬂozin 100 mg is
likely related to the fact that the simulations accounted for the
observed changes in the efﬁcacy of agents with SGLT2 inhibition
activity (such as canagliﬂozin) in patients with lower eGFR values
[45]. As a result, additional costs for insulin were incurred and
more hypoglycemic events occurred over time. In a sensitivity
analysis using the Latin American subsample data, both canagli-
ﬂozin doses dominated sitagliptin, likely because of the greater
efﬁcacy associated with canagliﬂozin 300 and 100 mg versus
sitagliptin 100 mg in Latin American patients enrolled in the
clinical study, suggesting that canagliﬂozin may be especially
favorable in the Latin American setting. Future analyses based on
a larger Latin American or Mexican population would be of value
given the relatively smaller sample size of this subsample
compared with the total trial population. In the scenario more
likely mimicking the real-world setting in Mexico (therapy inten-
siﬁcation threshold of HbA1c Z8.0%), where only a minority of
patients achieve the generally recommended HbA1c target of less
than 7.0% [11], canagliﬂozin was again very cost-effective.
There were several challenges in performing this analysis in
the Mexican health care setting. The evidence base on T2DM
outcomes in Mexico is limited (e.g., the most recent data on
goal attainment were from 2006). Enhanced data collection
in Mexico and Latin America, including detailed studies on
disutility weights for the complications associated with T2DM in
the Mexican population, would be beneﬁcial in terms of under-
standing the true burden of T2DM in this region and assessing
Table 5 – Sensitivity analyses: ICERs.
Scenario ICERs (LY), MXP ICERs (QALY), MXP
CANA
300 mg
CANA
100 mg
CANA
300 mg
CANA
100 mg
Base case 82,647 468,069 11,210 128,883
Baseline characteristics
SA1: Latin American subsample Dominating Dominating Dominating Dominating
Treatment rules
SA2: 8.0% HbA1c intensiﬁcation trigger 148,801 670,144 24,859 80,450
Time horizon
SA3: 10-y time horizon 166,014 1,192,916 14,839 81,149
SA4: 30-y time horizon 63,896 462,865 12,158 205,500
SA5: 40-y time horizon 64,579 392,635 13,931 186,313
Disutility associated with weight change
SA6: Alternative disutility estimate for weight loss per
BMI unit 425 kg/m2
82,647 468,069 23,301 Dominated
AEs potentially related to SGLT2 inhibition
SA7: Double costs 137,627 1,166,370 18,361 195,928
SA8: Double QALYs 80,267 804,182 10,921 154,759
BMI, body mass index; CANA, canagliﬂozin; HbA1c, glycated hemoglobin; ICER, incremental cost-effectiveness ratio; LY, life-year; MXP,
Mexican peso; QALY, quality-adjusted life-year; SA, sensitivity analysis; SGLT2, sodium glucose co-transporter 2.
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accurate costs in Mexico is complicated given the fragmented
health care system. Better unit cost data at the micro-level for the
Mexican context would improve estimation of the true economic
consequences of treatment intervention in T2DM.
This article described economic modeling of T2DM using
results from a clinical trial of canagliﬂozin versus sitagliptin with
local costs sourced from Mexican sources and a well-validated
model, ECHO-T2DM [47,48]. Findings suggest that canagliﬂozin is
likely to be cost-effective versus sitagliptin as an add-on therapy
to metformin in patients with T2DM from the perspective of the
Mexican health care system, owing to the differential beneﬁts of
improved control of hyperglycemia, hypertension, and weight
with canagliﬂozin versus sitagliptin.
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